LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-13

Study Completion Date

2029-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

NKG2D CAR-T(KD-025) in the Treatment of Advanced NKG2DL+ Solid Tumors

NCT06509490

Safety Issues

RECRUITING NA

NKG2D-CAR-NK92 Cells Immunotherapy for Solid Tumors

NCT05528341

Relapsed/Refractory Solid Tumors

RECRUITING PHASE1

NKG2D CAR-T(KD-025) in the Treatment of Relapsed or Refractory NKG2DL+ Tumors

NCT04550663

Solid Tumor Hepatocellular Carcinoma Colorectal Cancer +1 more

UNKNOWN PHASE1

Neoantigen-expanded Autologous Immune Cell Therapy

NCT05020119

Advanced Solid Tumor

UNKNOWN PHASE1

Vaccine Therapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00023985

Lung Cancer

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a dose-finding study of the investigational immunotherapy LEU011 in patients with NKG2DL-expressing solid tumours. The study will assess the safety and tolerability of LEU011 and is designed to determine the maximum tolerated dose (MTD) of LEU011.

Enrolled patients will undergo a whole blood procurement in order to manufacture LEU011. Subjects will receive LEU011 as a single IV dose following pre-conditioning chemotherapy and will be followed up for up to two years on this trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumor, Solid

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

Dose escalation study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LEU011

Infusion of target dose of LEU011

Group Type EXPERIMENTAL

LEU011

Intervention Type BIOLOGICAL

Immunotherapy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LEU011

Immunotherapy

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Histologically and/or cytologically confirmed solid tumour.
2. 18 years or older at time of consent
3. Relapsed/refractory solid tumour with no standard treatment options available or suitable (e.g. hypersensitivity reaction) and no curative approach possible.
4. Tumour expression of NKG2DL protein. The minimum requirement is the presence of one or more ligands on 10% or more cells, encompassing tumour and/ or stroma.
5. At least one target lesion measurable by RECIST v1.1 criteria on CT or MRI scanning
6. Eastern Co-operative Oncology Performance Status of 0-1.
7. Normal cardiac function as assessed by electrocardiography and echocardiography (ECHO. Left ventricular ejection fraction must be normal according to institutional values.
8. Baseline oxygen saturation of at least 95%
9. Haematology results must show:

* neutrophils \>1.5 x 109/L,
* platelets \>100 x 109/L,
* haemoglobin \>90g/L,
* INR \<1.3.
* Lymphocytes \>0.4 x 109/L
10. Biochemistry results must show:

* creatinine clearance \> 40 mL/min/1.73 m2 (calculated using the Chronic Kidney Disease Epidemiology \[CKD-EPI\] equation); bilirubin \<1.25 times ULN;
* ALT/ AST \<2.5 times ULN (\<5 times ULN if liver metastases present);
* Albumin \> 30g/L
11. Agree to use highly effective contraception (if applicable). Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test.
12. Disease amenable to biopsy.
13. Life expectancy of at least 6 months, in the investigator's opinion.
14. Written informed consent prior to any trial procedure and registration.
15. Subjects must agree to participate in an additional LTFU trial for up to 15 years after completion of this trial.

Exclusion Criteria

1. Subjects with HIV-1, HIV-2, HTLV-1, HTLV-2, active Hepatitis B, active Hepatitis C, or active Syphilis infection. Subjects without active Hepatitis B infection who are anti-core antibody positive can be considered for recruitment subject to suitability to receive nucleoside or nucleotide analogue prophylaxis.
2. Subject must not have received any anti-cancer treatment within 28 days of lymphodepletion (prior to LEU011). This criterion applies to the following additional therapies: (i) systemic corticosteroids (\> 20mg prednisolone/ day); (ii) any other systemic immunomodulatory agent (but see 11 below); (iii) radiotherapy; (iv) chemotherapy; (v) endocrine therapy or (vi) any investigational medicinal product.
3. Regarding (iv) Chemotherapy: Interval is extended to 6 weeks in the case of nitrosoureas. This criterion does not apply to the use of lymphodepleting chemotherapy prior to treatment with LEU011.
4. Prior LEU011 therapy. However, prior immune checkpoint blockade (e.g. anti-PD1, PD-L1 or CTLA-4) or immune agonist antibody therapy (e.g. anti-4-1BB, OX40, CD40 etc) does not preclude participation, but there must be a washout period of 30 days prior to treatment with LEU011.
5. Concurrent use of warfarin anticoagulant therapy and other coumarins is not permissible. Other classes of anticoagulant can be given.
6. The presence of major co-morbidity such as active major medical illness of the cardiovascular, respiratory or immune system that is likely to impair ability to undergo trial therapy, such as recent myocardial infarction, congestive cardiac failure, active gastrointestinal bleeding, active gastrointestinal ulceration, inflammatory bowel disease, ischaemic heart disease, peripheral arterial disease, pneumonitis, intestinal obstruction, sepsis or uncontrolled hypertension.
7. Clinically active autoimmune disease e.g., coeliac disease (an abnormal TTG antibody test precludes recruitment) or interstitial lung disease. Sub-clinical or quiescent autoimmune disease does not exclude from participation (e.g. euthyroid patients on thyroxine replacement therapy or patients with type 1 diabetes on insulin therapy).
8. Active infection that requires antimicrobial treatment.
9. Subjects who, in the Investigator's judgement, are unlikely to complete or comply with all protocol required study visits or procedures.
10. Hypersensitivity to any component of LEU011 (e.g. Albumin or DMSO allergy).
11. Cyclophosphamide or fludarabine allergy or contraindication.
12. Pregnancy.
13. Breastfeeding.
14. Subjects who have received a live vaccine four weeks or fewer before enrolment are ineligible for recruitment to the study. During treatment and for three months after treatment with fludarabine, administration of live vaccines is prohibited. None of the currently available covid 19 vaccines are considered to be live for this purpose since all are replication defective.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No